简介：Purpose:Anumberofdifferentclinicalcharacteristicshavebeenreportedtosinglycorrelatewiththerapeuticactivityofepidermalgrowthfactorreceptor(EGFR)tyrosinekinaseinhibitors(TKIs)inadvancednon-small-celllungcancer(NSCLC).Thisstudyaimedtoidentifypredictivefactorsassociatedwithprognosticbenefitsofgefitinib.Patientsandmethods:EGFRgenetypingin33advancedNSCLCpatientsreceivedgefitinib(250mg/day)wereanalyzedwithmutant-enrichedPCRassay.Gefitinibresponsewasevaluatedwithpotentialpredictivefactorsretrospectively.Results:Theoverallobjectiveresponserate(ORR)andmedianprogression-freesurvival(PFS)inthe33patientstreatedbygefitinibwere45.5%and3.0(2.0-4.0)months.TheORRandmedianPFSinEGFRgenemutationpatientsweresignificantlyhigher/longerthanthoseinEGFRgenewild-typepatients(P<0.01).Similarly,theORRandmedianPFSinnon-smokerpatientsweresignificantlyhigher/longerthanthoseinsmokerpatients(P<0.05,P<0.01,respectively).However,nodifferenceforORRandmedianPFSoccurredbetweenmaleandfemalepatients.LogisticmultivariateanalysisshowedthatonlyEGFRmutatedgenewassignificantlyassociatedwiththeORR(P<0.01).BothEGFRmutatedgeneandnon-smokerwerethemajorfactorsthatcontributedtoPFS(P<0.05).Conclusions:EGFRmutatedgeneandnon-smokerstatusarepotentialpredictorsforgefitinibresponseinNSCLCpatients.

简介：Objective:Theepidermalgrowthfactorreceptor(EGFR)inhibitorsmonoclonalantibodies(MoAbs)havealreadyshownthetherapeuticeffectivenessinpatientswithmetastaticcolorectalcancer(mCRC).Butmanypatientsresisttothetreatment.Theaimofthismeta-analysiswastoassessEGFRgenecopynumber(GCN)asacandidatepredictivebiomarkerforresistancetoanti-EGFRMoAbsinmCRCtreatment.Methods:SystematiccomputerizedsearchesofthePubMed,EMBaseandCochraneLibrarywereperformed.Theprimaryendpointwasobjectiveresponserate(ORR).Thesecondendpointsincludedprogression-freesurvival(PFS),andoverallsurvival(OS).Thepooledoddratio(OR)andpooledsensitivity,specificity,andsummaryreceiveroperatorcharacteristic(SROC)forORRwereestimated.Thepooledhazardratios(HR)forPFSandOSwerealsocalculated.Results:Fourteenstudieswith1,021patientswereincluded.IncreasedEGFRGCNwasassociatedwithincreasedORR(OR=6.905;95%CI:4.489-10.620).Itwasalsofoundinwild-typeKRASmCRCpatients,withthepooledORof8.133(95%CI:4.316-15.326).GCNhasmediumvalueforpredictingORR,withthepooledsensitivityof0.79(95%CI:0.73-0.84),thepooledspecificityof0.59(95%CI:0.55-0.62).InwildtypeKRASmCRCpatients,thesensitivityandthespecificitywere0.80(95%CI:0.70-0.87)and0.60(95%CI:0.53-0.66),respectively.IncreasedEGFRGCNwasassociatedwithincreasedPFS(HR=0.557;95%CI:0.382-0.732)andOS(HR=0.579;95%CI:0.422-0.737).Conclusions:Thismeta-analysissuggeststhatEGFRGCNrepresentsapredictivebiomarkerfortumorresponseinmCRCpatientstreatedwithMoAbsregardlessofKRASmutation.mCRCpatientswithincreasedEGFRGCNaremorelikelytohaveabetterresponse,PFS,andOSwhentreatedwithcetuximaborpanitumumab.